Leo Tseng

Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study

Rohit Loomba, Eric Lawitz, Juan P. Frías et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 91 citations

Hepatology, Pharmacology, Pharmacological Issue +7

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial

Deepak L. Bhatt, Harold Bays, Michael Miller et al. · Nature Medicine · 2023 · 86 citations · Full text

Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease

Sergei Pechenov, Jefferson D. Revell, Sarah Will et al. · Scientific Reports · 2021 · 71 citations · Full text

A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers

Raburn M. Mallory, Omar Ali, Therese Takas et al. · Biologicals · 2017 · 22 citations

Vaccination, Drug Safety, Healthy Adult Volunteers +7

The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers

Moti Rosenstock, Leo Tseng, Andrew L. Pierce et al. · Journal of Pharmacology and Experimental Therapeutics · 2023 · 20 citations · Full text